price predications, page-2

"We value PRR on the basis of a successful Phase IIb trial for CVac leading to a licensing deal for the product. Our 60 cent target price for PRR is at the lowpoint of our base case $0.63 / optimistic case $1.12 per share probability weighted DCF valuation range. We think that the current market capitalisation of Dendreon (Nasdaq: DNDN) of US$5.9bn is indicative of the potential of PRR. Dendreon’s Provenge cellular therapy, which is similar to
PRR’s, gained FDA approval in late April 2010."

http://www.swiftpage4.com/CampResource/2W0VYSM9HVFHYD2G/BIO/text.pdf

This quote was taken from a brokers report from 2010!
A LOT of boxes have been ticked since then!!!